Founded in 2002, Alnylam Pharmaceuticals, Inc. is a global biopharmaceutical company headquartered in Cambridge, Massachusetts, and is widely recognized as the pioneer of RNA interference therapeutics. The company is focused on developing transformative medicines designed to silence disease-causing genes, building a differentiated platform in genetic and other serious diseases through deep expertise in RNAi science, drug development, and commercial execution. Alnylam has delivered six approved medicines, has therapies available in more than 70 countries, and employs more than 2,100 full-time people worldwide. In 2025, the company reported total revenues of USD 3.714 billion, reflecting the scale and momentum of one of the biotechnology sector’s most important innovation platforms.
Updated 2026-03-19